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CLINICAL AND POPULATION STUDIES
Genome-Wide Association Study and 
Identification of a Protective Missense Variant on 
Lipoprotein(a) Concentration
Protective Missense Variant on Lipoprotein(a) Concentration—Brief Report
M. Abdullah Said,* Ming Wai Yeung,* Yordi J. van de Vegte, Jan Walter Benjamins , Robin P.F. Dullaart, Sanni Ruotsalainen,  
Samuli Ripatti , Pradeep Natarajan , Luis Eduardo Juarez-Orozco , Niek Verweij, P. van der Harst
OBJECTIVE: Lipoprotein(a) (Lp[a]) is associated with coronary artery disease (CAD) but also to LDL (low-density lipoprotein) 
cholesterol. The genetic architecture of Lp(a) remains incompletely understood, as well as its independence of LDL cholesterol 
in its association to CAD. We investigated the genetic determinants of Lp(a) concentrations in a large prospective multiethnic 
cohort. We tested the association for potential causality between genetically determined higher Lp(a) concentrations and 
CAD using a multivariable Mendelian randomization strategy.
APPROACH AND RESULTS: We studied 371 212 participants of the UK Biobank with available Lp(a) and genome-wide genetic data. 
Genome-wide association analyses confirmed 2 known and identified 37 novel loci (P<5×10−8) associated with Lp(a). Testing 
these loci as instrumental variables in an independent cohort with 60 801 cases and 123 504 controls, each SD genetically 
elevated Lp(a) conferred a 1.30 ([95% CI, 1.20–1.41] P=5.53×10−11) higher odds of CAD. Importantly, this association was 
independent of LDL cholesterol. Genetic fine-mapping in the LPA gene region identified 15 potential causal variants. This 
included a rare missense variant (rs41267813[A]) associated with lower Lp(a) concentration. We observed a strong interaction 
between rs41267813 and rs10455872 on Lp(a) concentrations, indicating a protective effect of rs41267813(A).
CONCLUSIONS: This study supports an LDL cholesterol–independent causal link between Lp(a) and CAD. A rare missense variant 
in the LPA gene locus appears to be protective in people with the Lp(a) increasing variant of rs10455872. In the search for 
therapeutic targets of Lp(a), future work should focus on understanding the functional consequences of this missense variant.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: causality ◼ coronary artery disease ◼ genetics ◼ lipoproteins ◼ polymorphism, single nucleotide
Lipoprotein(a) (Lp[a]) is a macromolecular com-plex that consists of an LDL (low-density lipopro-tein) particle to which a glycoprotein—called apo(a) 
(apolipoprotein[a])—is linked via a disulfide bond to 
the constitutional apolipoprotein-B(100)—the principal 
protein that is carried on LDL particles. Elevated levels 
of Lp(a) have been associated with an increased risk of 
coronary artery disease (CAD) in epidemiological studies 
and meta-analyses.1 More recently, Mendelian random-
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have suggested a causal link between elevated Lp(a) 
levels and CAD.2–6 MR analyses use genetic variants, 
which are randomly distributed and fixed at conception, 
as instrumental variables for a risk factor of interest to 
minimize confounding and reversed causality bias and, 
therefore, have the potential to provide evidence on the 
putative causal links with a disease.7
The LPA gene (6q25.3-q26) encodes the apo(a) com-
ponent, which has evolved from the plasminogen gene 
and contains a variable number of KIV (kringle IV) repeats. 
This includes the highly polymorphic KIV2 (KIV-subtype 
2), which can have multiple repeats ranging from 1 to 
over 40 copies.8 The number of KIV2 repeats have been 
inversely associated with Lp(a) concentrations.8 Twin 
studies have suggested that >90% of variance is geneti-
cally determined.9 Genome-wide association studies 
(GWAS) of Lp(a) concentrations have thus far identified 
single-nucleotide polymorphisms (SNPs) outside KIV2, 
explaining 21% to 63% of the variance in Lp(a).2,3,6,10 Yet, 
several aspects of the genetic architecture and causal 
relationships of Lp(a) remain to be better understood. Not 
only 30% of variance remains to be explained but also the 
causal mechanism marked by the strongest associated 
SNP (the intronic rs10455872) is not well understood, 
and few independent genetic variants affecting Lp(a) 
concentrations outside the LPA gene region are known. 
Finally, although the association between Lp(a) and CAD 
has been suggested not to be affected by LDL choles-
terol (LDL-C)–lowering therapies,3,11,12 additional lines of 
evidence could be obtained by multivariable MR (MVMR) 
taking LDL-C into account in this association.
We aimed to better characterize the genetic architec-
ture underlying Lp(a) concentrations across the whole 
genome in a large prospective observational study. Fur-
ther, to increase our understanding of the functional vari-
ants in the LPA gene, we applied genetic fine-mapping by 
incorporating exome sequencing data. Finally, we applied 
a 2-sample MVMR approach to investigate whether the 
genetic variants associated with Lp(a) influence CAD 
independently from LDL-C.
METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Study Population
The UK Biobank study has been described in detail previously.13 
The UK Biobank study is a population-based prospective cohort 
in the United Kingdom in which >500 000 individuals aged 
between 40 and 69 years were included from 2006 to 2010. 
All participants have given informed consent.14 The study has 
approval from the North West Multi-Centre Research Ethics 
Committee for the United Kingdom, from the National Information 
Governance Board for Health and Social Care for England and 
Wales, and from the Community Health Index Advisory Group 
for Scotland.15 Ethnic background was determined using self-
reported data at the assessment center (field ID 2100).
Lp(a) and LDL-C Measurement
Lp(a), in nmol/L, was measured using an immunoturbidimet-
ric assay (Randox Bioscience, United Kingdom). LDL-C (in 
Nonstandard Abbreviations and Acronyms
apo(a) apolipoprotein(a)
CAD coronary artery disease
CARDIoGRAM 
plusC4D  Coronary Artery Disease Genome 
Wide Replication and Meta-
Analysis Plus the Coronary Artery 
Disease Genetics
GWAS genome-wide association study
HDL high-density lipoprotein
KIV kringle IV
KIV2 kringle IV subtype 2
LD linkage disequilibrium
LDL low-density lipoprotein
LDL-C low-density lipoprotein cholesterol
LDLR low-density lipoprotein receptor
Lp(a) lipoprotein(a)
MR Mendelian randomization
MR-PRESSO  Mendelian Randomization Pleiot-
ropy Residual Sum and Outlier
MVMR  multivariable Mendelian 
randomization
PCSK9  proprotein convertase subtilisin-
kexin type 9
SNP single-nucleotide polymorphism
SuSiE Sum of Single Effects
WES whole-exome sequencing
Highlights
• Leveraging data from over 370 000 UK Biobank 
participants, we found 37 novel genetic variants 
associated with lipoprotein(a) values.
• We identified a missense variant that was associ-
ated with strong lipoprotein(a)-lowering effects in 
carriers of the lipoprotein(a) increasing rs10455872 
variant.
• Mendelian randomization analyses in over 60 000 
cases and 123 000 controls provide evidence for a 
causal link between genetically determined higher 
lipoprotein(a) and increased risk of coronary artery 
disease, independently of LDL (low-density lipopro-
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mmol/L) was measured using an enzymatic selective protec-
tion assay. Both lipoproteins were measured on a Beckman 
Coulter AU5800 (Beckman Coulter, Ltd, United Kingdom).
Whole-Exome Sequencing
Full details of the whole-exome sequencing (WES) in the UK 
Biobank have been reported previously.16 In short, WES was 
performed using IDT xGen Exome Research Panel v1.0, tar-
geting 38 997 831 bases in 19 396 genes. Exomes were cap-
tured including 100 bp flanking regions. Coverage exceeded 
20× at 94.6% of sites on average in all samples and among 
targeted bases. All variants passed quality control criteria, had 
<10% individual and variant missingness, and Hardy Weinberg 
P>10−15. Compared with the imputed sequence data, the WES 
data contain over 7× more coding variants and 20× more loss-
of-function variants. A total of 4.7M variants within targeted 
regions and 9.7M across all covered bases were identified and 
mapped to a full CRCh38 reference in the used functionally 
equivalent pipeline. At the time of writing, 7554 targets were 
incorrectly mapped and removed from the analysis as recom-
mended by the UK Biobank. This resulted in a 0.48% loss 
of variants overall. The LPA gene region was not affected. 
At the time of analysis, WES data were available for 49 960 
participants.
Genotyping and Imputation
The UK Biobank participants were genotyped using custom 
Affymetrix Axiom (UK Biobank Lung Exome Variant Evaluation 
or UK Biobank) arrays with >95% common content. The geno-
typing methods, arrays, and quality control procedures have 
been extensively described previously.17
Functional Annotation of Variants
Candidate genes at each locus were prioritized based on prox-
imity by selecting the nearest protein coding gene and any addi-
tional gene within 10 kb of the sentinel SNP. Variants identified 
using fine-mapping were annotated using Ensembl Variant 
Effect Predictor18 for allele frequency, variant consequences 
from dbNSFP and MaxEntScan, and effect prediction by vari-
ous tools including CADD (Combined Annotation Dependent 
Deletion), SIFT (Sorting Intolerant From Tolerant), PolyPhen, 
Condel (CONsensus DELeteriousness), and LoFtool.
MR Assumptions
SNPs were considered valid instrumental variables for the MR 
analyses if (1) they were strongly associated with the risk factor 
of interest, (2) the SNPs were not associated with confounders 
of the association between risk factor and outcome, and (3) the 
SNPs affected the outcome exclusively through their effect on 
the risk factor being studied (Figure I in the Data Supplement).
Statistical Analysis
All genetic analyses were adjusted for age at inclusion, squared 
age at inclusion, genotyping array, the first 30 principal compo-
nents to adjust for population stratification (provided by the UK 
Biobank), and lipid-lowering drug usage at inclusion. The study 
design is depicted schematically in Figure 1.
Genome-Wide Association Studies
We performed GWAS for inverse rank normalized serum Lp(a) 
concentrations. GWAS using the genotyped and imputed data 
were performed using BOLT-LMM v2.3.119 and included 19M 
SNPs. To obtain a set of independent SNPs associated with 
Lp(a), SNPs that passed the genome-wide significance thresh-
old of P<5×10−8 were clumped together based on linkage 
disequilibrium (LD) r2>0.005 and 2.5-Mb distance using the 
clumping procedure in PLINK 1.9. A locus was defined as a 
1-Mb region surrounding the most significant SNP. SNPs with 
minor allele frequencies <0.005 or INFO scores <0.3 were 
excluded. The proportion of additive variance explained by 
the top variants was estimated by fitting a multivariable linear 
regression model on Lp(a) concentration, assuming an additive 
genetic model for the genetic variants and using the covariates 
as described above.
Genetic Fine-Mapping
To allow statistical fine-mapping with a higher variant density, 
the WES data were overlaid with the genotyped data, using 
the WES data when a variant was present in both sources 
(Figure 1). LiftOver20 was used to convert the genotype data 
from GRCh37 to GRCh38. Genetic fine-mapping in the merged 
data was subsequently performed using 2 Bayesian fine-map-
ping methods to identify putative causal variants, namely the 
Sum of Single Effects21 (SuSiE) model and FINEMAP.22 SuSiE 
implements an iterative Bayesian stepwise selection procedure, 
which creates a number of credible sets with independent or 
highly correlated variables of which one has a nonzero effect, 
while all are associated with Lp(a). FINEMAP performs a shot-
gun stochastic search to efficiently evaluate possible causal 
configurations of SNPs. Fine-mapped variants were annotated 
using Variant Effect Predictor for the variant’s primary effect 
prediction. Genetic fine-mapping was performed across a 1-Mb 
region surrounding the sentinel SNP rs10455872 in the LPA 
region. After selecting individuals with WES data who were also 
included in the GWAS, PLINK 2.0 was used to perform a linear 
regression analysis on the inverse rank normalized Lp(a) con-
centrations. Variants with minor allele frequencies >0.0005 and 
genotype missingness <0.1 were included, amounting to 7173 
variants for fine-mapping. Pairwise LD estimates were calcu-
lated from the genotype dosages for individuals included in the 
GWAS, rather than using external reference panels, which may 
be inaccurate when scaled to large sample sizes.23 In the sce-
nario in which multiple SNPs were in a credible set identified by 
SuSiE, the SNP with the highest posterior inclusion probability 
was taken as the most likely causal variant for that set. SuSiE 
was performed first, and the number of credible sets was taken 
forward as the maximum number of allowed causal SNPs in 
FINEMAP. SNPs in the top causal configuration in FINEMAP 
were taken as likely causal variants. SNPs identified by both 
SuSiE and FINEMAP based on identical rsID or r2>0.8 were 
prioritized and considered more likely to be causal. In the case 
of selection based on r2, the SNP with the highest posterior 
inclusion probability as indicated by SuSiE was selected.
MR Analyses
We performed univariable and multivariable 2-sample MR analy-
ses to investigate evidence for causal links between genetically 
determined elevated Lp(a) and CAD. MR analyses were per-
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Disease Genome Wide Replication and Meta-Analysis Plus the 
Coronary Artery Disease Genetics (CARDIoGRAMplusC4D) 
consortium (123 504 controls and 60 801 [33.0%] cases).24 
Sentinel SNPs identified in the GWAS on Lp(a) were used as 
instrumental variables for Lp(a). SNPs that were not available 
in CARDIoGRAMplusC4D were replaced with proxies in LD 
of r2>0.8 or excluded from the MR if no eligible proxies were 
available. Harmonization of SNP effects was performed using 
the built-in feature of the TwoSampleMR package in R. The 
framework used for the MR and corresponding heterogene-
ity and sensitivity analyses is depicted in Figure II in the Data 
Supplement. F statistics25 and I2GX
26 were calculated to assess 
potential weak instrument bias. I2 index,27 Cochran Q, Rücker Q′, 
and Q-Q′28 were used as heterogeneity tests. Univariable MR 
analyses to investigate evidence for a potential causal associa-
tion between genetically determined Lp(a) and CAD included 
fixed and random-effects inverse-variance weighted (IVW) MR, 
MR-Egger,28 MR-Steiger,29 MR Pleiotropy Residual Sum and 
Outlier30 (MR-PRESSO), and median- and mode-based estima-
tor MR analyses31 as outlined in the Data Supplement. MVMR-
IVW analyses were performed to estimate the direct effect of 
Lp(a) on CAD not mediated by the effect of LDL-C on CAD and 
the direct effect of LDL-C on CAD not mediated by the effect 
of Lp(a) on CAD (Figure I in the Data Supplement). By condi-
tioning the effects of each SNP on LDL-C in the UK Biobank, 
the direct effect of Lp(a) on CAD in CARDIoGRAMplusC4D 
can be estimated. Qx1 and Qx2 were calculated to test for weak 
instrument bias and Qa to test for pleiotropy.
32 MVMR-Egger 
and MR-PRESSO were performed as sensitivity analyses. 
Odds ratios with 95% CIs are presented for the MR outcomes. 
We considered a conservative α of 0.00533 instead of 0.05 to 
provide evidence for a significant causal association. MR analy-
ses were performed using the TwoSampleMR (version 0.4.26), 
MR-PRESSO (version 1.0), MendelianRandomization (version 
0.4.1), and MVMR (version 0.1) packages in R, version 3.5.1.
RESULTS
Cohort Characteristics
A total of 371 212 individuals were included in the analy-
ses (Figure III in the Data Supplement). Baseline char-
acteristics are shown in Table I in the Data Supplement. 
Compared with women, men were more often diagnosed 
with hyperlipidemia and CAD, next to having a higher 
blood pressure and BMI. Lp(a) concentrations ranged 
between 3.8 and 189 nmol/L, with a median value of 
21.1 nmol/L (interquartile range, 9.58–61.9). A total of 
723 individuals with Lp(a) concentrations had no LDL-C 
values available. Among the 370 489 individuals with 
LDL-C values, Lp(a) was correlated with LDL-C with a 
Pearson ρ of 0.081 (Figure IV in the Data Supplement).
GWAS on Lp(a)
The GWAS identified 177 genome-wide significant SNPs 
in 39 loci associated with Lp(a) (Figure V in the Data 
Supplement; Table II in the Data Supplement). Notably, 
37 of these have not been reported previously. Two vari-
ants in CHKA and PEMT were not associated with other 
Figure 1. Schematic study design.
Schematic overview of the study design including (A) genome-wide association analyses, (B) phenotypic associations between lipoprotein(a) 
(Lp[a]) and coronary artery disease (CAD), (C) genetic fine-mapping analyses, and (D) Mendelian randomization analyses using the genetic 
variants associated with Lp(a) as instrumental variables to investigate the association with coronary artery disease. LDL-C indicates low-density 
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lipid traits (LDL-C, apolipoprotein-B, HDL [high-density 
lipoprotein] cholesterol, triglycerides, and cholesterol) at 
P<0.05 (Table III in the Data Supplement). We identi-
fied 2 sentinel SNPs with extreme P, namely the previ-
ously identified intronic rs10455872 (P=4.3×10−19,380) 
and rs1065853 (P=1.3×10−542), near the APOE gene. 
Regional association plots for each locus are presented 
in Figure VI in the Data Supplement and the QQ-plot 
in Figure VII in the Data Supplement. We replicated the 
novel variants in 7044 participants of the FINRISK study 
from Zekavat et al4 and found that 2 SNPs were nomi-
nally significant (Table IV in the Data Supplement). The 
39 top variants explained 24.9% of the phenotypic vari-
ance of Lp(a) level, the vast majority (24.4%) of which 
was attributable to rs10455872. Because of this, fine-
mapping was performed solely for the LPA region cen-
tered around rs10455872.
Genetically Determined Lp(a) and CAD
The sentinel SNPs were tested for their association with 
CAD using a 2-sample MR approach in the CARDIo-
GRAMplusC4D data. In total, 38 variants or their LD bud-
dies were available in CARDIoGRAMplusC4D (Table V in 
the Data Supplement). Heterogeneity and pleiotropy test 
results are presented in Table VI in the Data Supplement. 
In the univariable MR setting, there was no evidence for 
weak instrument bias and low chances of measurement 
error in MR-Egger. In the fixed-effects MR-IVW model, 
there was potential balanced horizontal pleiotropy based 
on the I2 and significant Cochran Q but no evidence 
for unbalanced horizontal pleiotropy (MR-Egger inter-
cept P>0.05). Therefore, despite the significant Q-Q′, 
the random-effects MR-IVW estimate was considered 
the causal estimate. Using this model, an SD increase 
in genetically determined Lp(a) was associated with a 
1.42 ([95% CI, 1.26–1.59] P=5.62×10−9; Figure VIII in 
the Data Supplement) higher odds of CAD. MR-Steiger 
filtering, MR-PRESSO, and weighted and mode-based 
estimator MR analyses resulted in similar estimates 
(Table VII in the Data Supplement). Heterogeneity test 
results for the MVMR are presented in Table VIII in the 
Data Supplement. Qx1 and Qx2 were both higher than 
the critical value, indicating the SNPs could predict both 
Lp(a) and LDL-C. There was no evidence for unbalanced 
horizontal pleiotropy. The value for the adjusted Q statis-
tic, however, was higher than the critical value. The null 
hypothesis that there is no heterogeneity could, there-
fore, not be rejected. Using the IVW method, each SD 
of genetically determined higher Lp(a) remained associ-
ated with a 1.30 ([95% CI, 1.20–1.41] P=5.53×10−11) 
higher odds of developing CAD, independently of the 
effects of LDL-C (Table IX in the Data Supplement; Fig-
ure IX in the Data Supplement). After filtering one outlier 
(rs3785549), MR-PRESSO indicated an odds ratio of 
1.42 ([95% CI, 1.26–1.60] P=1.03×10−6).
Phenotypic Lp(a) and CAD
We tested the association between the measured Lp(a) 
concentrations with new-onset CAD in the UK Biobank. 
Of 356 766 individuals with no history of CAD, 14 710 
individuals were diagnosed with CAD during a median 
(interquartile range) 8.1 (7.5–8.6) years of follow-up. 
There was a linear increase in risk of CAD per decile 
of Lp(a) when compared with people in the lowest 
decile, with a hazard ratio of 1.34 ([95% CI, 1.25–1.44] 
P=3.64×10−16) in the highest decile after adjusting 
for age, sex, and lipid-lowering drug usage at inclusion 
(Table X in the Data Supplement).
Genetic Fine-Mapping Analyses
Genetic fine-mapping analyses in the merged WES and 
genotype data were performed in a subset of 36 773 
individuals who were also included in the GWAS. The 
linear regression performed in the LPA region resulted 
in 3313 variants associated at a significant P<6.9×10−7 
(Bonferroni-corrected P=0.005/7283 analyzed variants). 
In the merged data, rs10455872 remained the strongest 
associated variant (β=1.44; SE=0.01; P=2.02×10−2,290). 
Genetic fine-mapping using SuSiE yielded 30 credible 
sets (Table XI in the Data Supplement) of which 20 con-
tained single SNPs and 9 contained <5 SNPs. Together, 
SuSiE and FINEMAP identified 47 variants, but only 
15 variants were identified through both methods and 
were prioritized (Table XII in the Data Supplement). This 
included rs118039278 (PGWAS=1.1×10
−19,360), which is in 
perfect LD with rs10455872 in Europeans. The variants 
identified by SuSiE, FINEMAP, SuSiE and FINEMAP, and 
all 47 variants together explained, respectively, 51.4%, 
49.6%, 46.6% and 52.1% of variance in Lp(a). Variant 
Effect Predictor annotation of the prioritized SNPs indi-
cated 2 missense variants that were both reported as 
deleterious by SIFT and Condel and probably damaging 
by PolyPhen (Table XIII in the Data Supplement).
Protective Variant on Lp(a) Concentration
When plotting the Lp(a) distribution per Lp(a) increas-
ing G allele of rs10455872, a small group of individuals 
(n=2314 [4.8%]) had low Lp(a) concentrations (median 
[interquartile range], 8.6 [5.4–13.6] nmol/L) despite hav-
ing 1 or 2 Lp(a) increasing G alleles (Figure 2). To inves-
tigate whether the low Lp(a) concentrations observed in 
heterozygous carriers of rs10455872 were the result 
of protective effects of variants within or outside the 
LPA gene region, we compared the distribution of the 
weighted GRS for low (<25 nmol/L) and elevated (>50 
nmol/L) concentrations using the 39 GWAS variants 
across the whole genome and the 15 fine-mapped vari-
ants in the LPA region. The distribution of the GRS for 
both the low and elevated concentrations deviated using 
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This suggests that the protective variant resides in the 
LPA region. Hence, we prioritized the fine-mapped vari-
ants with functional consequences. Because of the small 
percentage of individuals with low Lp(a) values despite 
the G allele(s) of rs10455872, we disregarded SNPs 
with minor allele frequencies >5%. Two missense vari-
ants, rs41267807 and rs41267813, remained, and their 
effects on Lp(a) independently of rs10455872 were esti-
mated (Table XIV in the Data Supplement). No interac-
tion existed between rs41267807 with rs10455872, and 
there was only a minor shift toward lower values in people 
with 1 or 2 Lp(a)-lowering C alleles of rs41267807. Much 
stronger effects were observed for rs41267813. Not only 
was the minor allele (A) of this variant associated with a 
strong Lp(a)-lowering effect but there was also a strong 
interaction between rs41267813 and rs10455872 
(P=3.75×10−19; Figure 2). Among individuals who were 
heterozygous for rs10455872, as well as for rs41267813, 
the median Lp(a) concentration (9.44 [5.41–19.41] 
nmol/L) was over 13× lower compared with individuals 
with rs41267813(GG) (median, 127.94 [100.7–155.15] 
nmol/L; Figure 2). Median Lp(a) concentrations for each 
genotype of rs10455872 and rs41267813 are pro-
vided in Table XV in the Data Supplement. When the 
model with all 15 overlapping fine-mapped SNPs was 
refitted using a multivariable regression model, each 
A allele of rs41267813 had a β of −1.99 (SE, 0.023; 
P=3.66×10−48), which was larger than the effect of 
rs118039278 (β=1.38 [SE=0.005]; P=1.41×10−82; 
Table XVI in the Data Supplement), which is in almost 
perfect LD with rs10455872. Among participants hetero-
zygous for rs10455872, LDL-C values were comparable 
in noncarriers of rs41267813 (mean, 3.57 [SD=0.85]) 
and heterozygous carriers of rs41267813 (mean, 3.60 
[SD=0.86]). The proportion of individuals in the UK Bio-
bank heterozygous for rs10455872 with CAD in their 
history or during follow-up was lower among individuals 
with the missense variant compared with those without 
(6.5% versus 9.1%; 1-sided Fisher exact, P=0.03). How-
ever, we did not find evidence for an interaction between 
Figure 2. Missense variant rs41267813 in KIV9 (kringle IV subtype 9).
A, The schematic position of rs41267813 in KIV9 in the apolipoprotein(a) tail of lipoprotein(a) (Lp[a]). B, Distribution of Lp(a) for different 
genotypes of rs10455872. C, Interaction between rs10455872 and rs41367813. No individuals with 2 A alleles of rs41267813 were 
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rs10455872 and rs41267813 on CAD risk in logistic 
regression analyses in the UK Biobank. When looking pri-
marily at the effect of rs41267813(A) and not taking into 
account the interaction with the rs10455872 genotype, 
individuals with rs41267813(A) had a lower prevalence of 
CAD compared with noncarriers of the A allele, although 
this difference was not statistically significant (6.7% ver-
sus 7.9%; 1-sided Fisher exact P=0.16). Unfortunately, 
rs41267813 was not available in the CARDIoGRAM-
plusC4D cohort and could, therefore, not be looked up 
to assess the effect on CAD. In our sample, no individual 
had 2 A alleles of rs41267813. Among individuals with 
no A alleles of rs41267813 but with 1 or 2 G alleles of 
rs10455872, a total of 1072 (2.4%) remained with Lp(a) 
concentrations <25 nmol/L.
DISCUSSION
We explored the genetic architecture of Lp(a) in over 
370 000 individuals through GWAS. Genetic fine-map-
ping analyses identified a rare missense variant in the 
LPA locus with protective effects in individuals with Lp(a) 
increasing G alleles of the well-established Lp(a) SNP 
rs10455872.2 We provide a novel line of evidence sup-
porting an LDL-C independent causal link between Lp(a) 
biology and the development of CAD.
Comparison With Previous Studies
We identified 39 variants that were strongly associated 
with Lp(a) across the genome. Notably, the majority of 
these variants (37 of 39) had not been reported previ-
ously; only 1 variant in the LPA locus and 1 variant in prox-
imity of the APOE locus have been published before.2,4,6 
Two of the novel variants are located in CHKA and PEMT 
(phosphatidylethanolamine N-methyltransferase), which 
both play important roles in phospholipid biosynthesis 
pathways, were not associated with other lipid traits in 
the UK Biobank. CHKA plays an important role in the 
cytidine diphosphate-choline pathway, which is the major 
pathway for the biosynthesis of phosphatidylcholine.34 
Phosphatidylcholine is a major membrane phospholipid 
of all lipoproteins and plays essential roles in mem-
brane structure and permeability. PEMT is responsible 
for the alternative pathway (PEMT pathway) for phos-
phatidylcholine biosynthesis in the liver and contributes 
to ≈30% of phosphatidylcholine biosynthesis.34 Neither 
gene has been previously reported in GWAS on Lp(a). 
PEMT, next to APOH, PGS1, APOE, PGS1, LDLR (LDL 
receptor), PCSK9 (proprotein convertase subtilisin-kexin 
type 9), APOB, ABCA6, PPP1R3B, and LPA, has, how-
ever, been associated to LDL-C.35,36 Of these, LDLR and 
PCSK9 have a role in the reduction of Lp(a).37 PCSK9 
plays a role in the modulation of Lp(a) concentrations, 
and its inhibition leads to a reduction in Lp(a) concen-
trations. This is likely due to an increased expression 
of LDLR, allowing more internalization of LDL particles. 
In turn, more LDLRs become available and with higher 
affinity ligands that can more easily bind Lp(a) particles. 
This is important, as Lp(a) particles have a lower affin-
ity to LDLR compared with LDL particles.37 One previ-
ous GWAS on Lp(a) reported a variant on chromosome 
11 in the APOC3 locus,38 which was not available in the 
UK Biobank and could, therefore, not be replicated. Sub-
stantial advantages of the present study are the much 
larger sample size in comparison with previous GWASs 
on Lp(a)2,4,6 and the utilization of a single sample study 
design that overcomes potential drawbacks of meta-
analyses in terms of power and heterogeneity among 
studies. We found that the variants outside the LPA locus 
had a smaller effect on the variance in Lp(a) levels, which, 
for the vast majority, was accounted for by rs10455872. 
Fine-mapping around rs10455872 resulted in credible 
sets, which explained 46.6% to 52.1% of variance in 
Lp(a), which is comparable to previous estimates.3,6
Since evidence of the association between Lp(a) and 
CAD has been described previously in multiple stud-
ies,2,4,6 we proceeded sequentially to validate prior find-
ings and further disentangle the relationships between 
Lp(a), LDL-C, and CAD. We found a similar estimate as 
in previous studies, with each SD increase (correspond-
ing to an 83.83 nmol/L change in Lp[a]) in genetically 
determined Lp(a) translating in a 42% ([95% CI, 26%–
59%] P=5.6×10−9) increased risk of CAD. A previous MR 
study found that the causal estimate of Lp(a) and CAD 
was independent of LDL-C levels using rs12916 to mimic 
the effect of statins.3 However, this method does not allow 
for investigation of the direct effect of Lp(a) on CAD (ie, 
the effect not driven by LDL) and differentiation between 
different scenarios encountered within epidemiological 
studies (confounding, collider, pleiotropy, and mediation). 
Here, using an MVMR approach, we found that Lp(a) was 
robustly associated with CAD risk (odds ratio, 1.30 [95% 
CI, 1.20–1.41]; P=5.5×10−11) independently from LDL-C. 
The present study provides strong supportive evidence for 
a direct causal role of Lp(a) in the development of CAD.
Protective Missense Variant in the LPA Gene
Although rs10455872 is the major genetic determinant 
for Lp(a) concentrations (explaining 24.4% of its vari-
ance), we found individuals that carried the increasing 
allele still have low Lp(a) concentrations, not consistent 
with an additive model. We found that rs41267813—one 
of the fine-mapped candidate causal variants—could 
explain this phenomenon and showed strong interac-
tion effects with rs10455872 on Lp(a) concentrations. 
rs41267813 causes a change from a histidine residue 
to tyrosine on exon 28. Exons 28 and 29 together form 
KIV9 of the apo(a) tail, which contains an extra unpaired 
cysteine residue responsible for the linkage between 
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bond.39 rs41267813 was significantly more associated 
with lower Lp(a) values among individuals carrying at 
least 1 G allele of rs10455872. This effect-modifying 
SNP was previously reported to be associated with Lp(a) 
in an independent cohort (n=48 333) but not further 
investigated.3 A separate study also reported the asso-
ciation between rs41267813(A) and lower LDL-C levels 
but could not confirm the association with Lp(a) concen-
tration as this measure was unavailable.40 We could not 
test the association between rs41267813 and Lp(a) iso-
form size, as this was not measured in the UK Biobank. A 
potential explanation for the current findings is that indi-
viduals with the missense variant and rs10455872(G) 
have large isoform sizes and, therefore, low Lp(a) con-
centrations.41 This should be studied in a sufficiently 
large separate cohort with rs41267813 and isoform size 
data available. The deep dive of this variant in the present 
study, however, highlights it as a potential protective vari-
ant that may be of special interest to therapeutic devel-
opments aimed at lowering Lp(a) concentrations.
Clinical Perspectives
This study provides further evidence for the causal asso-
ciation between Lp(a) and CAD. Screening for patients 
with high Lp(a) values is not a common practice, as Lp(a) 
is relatively refractory to both lifestyle and drug interven-
tions. High Lp(a) values may, however, identify high-risk 
individuals that could benefit from early treatment. Future 
therapies include antisense oligonucleotide therapy, 
which shows promise in clinical trials.42 This study further 
highlights the importance of finding Lp(a)-lowering ther-
apies. The missense variant reported in this study may be 
a potential drug target.
Strengths and Limitations
Major strengths of the present study are the large sam-
ple size of the UK Biobank, fine-mapping of the LPA 
gene region using 2 Bayesian fine-mapping approaches, 
identification of a protective missense variant, and 
MVMR strategy to investigate causal links between Lp(a) 
with CAD in an independent cohort with over 60 000 
cases and 120 000 controls. Bayesian fine-mapping 
approaches are superior to conditional analyses used in 
previous reports and simulations,3,4,6,43 as the latter fail 
to provide probabilistic measures of causality for vari-
ants. There are also limitations. We found evidence for 
potential heterogeneity in the MR analyses, meaning 
pleiotropy cannot be ruled out. However, we, therefore, 
provided a framework for the MR analyses to report 
the correct estimate per degree of pleiotropy. In addi-
tion, sensitivity analyses showed consistent results with 
respect to the main analyses. We could not analyze the 
KIV2 copy number nor test variants in the KIV2 region as 
these data were not available in the UK Biobank. We, 
however, aimed to provide some insight into the asso-
ciation between rs41267813 and the KIV2 copy number 
using rs10455872, which has been reported to be tag-
ging the number of KIV2 copies.
2
Conclusions
In conclusion, this study determined genetic variants 
associated with Lp(a) and found additional strong sup-
port for a causal link with CAD, independent of LDL-C. 
Furthermore, we identified a novel rare missense vari-
ant, rs41267813(A), in the LPA gene locus with protec-
tive effects in people with Lp(a) increasing G alleles of 
rs10455872. In the continuing search for therapeutic 
targets of Lp(a), this missense variant may be of interest.
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